Evidence map›Paper›PMID 27927191›Full record

ArticleBMC cancer2016

Somatostatin signaling via SSTR1 contributes to the quiescence of colon cancer stem cells.

Shirin R Modarai, Lynn M Opdenaker, Vignesh Viswanathan, Jeremy Z Fields, Bruce M Boman

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Cancers · 2024
    Article
  11. Article
  12. Somatostatin and Somatostatin Receptors in Tumour Biology.International journal of molecular sciences · 2023
    Review
  13. Article
  14. Effects of hormones on intestinal stem cells.Stem cell research & therapy · 2023
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Knocking OutCancer management and research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shirin R ModaraiDepartment of Biological Sciences, University of Delaware, 118 Wolf Hall, Newark, DE, 19716, USA.
Lynn M OpdenakerDepartment of Biological Sciences, University of Delaware, 118 Wolf Hall, Newark, DE, 19716, USA.
Vignesh ViswanathanDepartment of Biological Sciences, University of Delaware, 118 Wolf Hall, Newark, DE, 19716, USA.
Jeremy Z FieldsCATX Inc., Gladwyne, PA, 19035, USA.
Bruce M BomanDepartment of Biological Sciences, University of Delaware, 118 Wolf Hall, Newark, DE, 19716, USA. brucemboman@gmail.com.
University of Delaware · US

Funding

Predictive Modeling & Optimal Control Framework for Model-Based Epidemic Response in DelawareP20GM103446 · NIGMS · UNIVERSITY OF DELAWARE · PI MELINDA K DUNCAN · 2012 to 2026
$67.2M
NIGMS NIH HHS P20 GM103446
6 · The paper itself

Abstract

backgroundNeuroendocrine cells (NECs) reside adjacent to colonic stem cells (SCs) in the crypt stem cell (SC) niche, but how NECs are involved in regulation of SCs is unclear. We investigated NECs expressing somatostatin (SST) and somatostatin receptor type 1 (SSTR1) because SST inhibits intestinal proliferation. HYPOTHESIS: SSTR1 cells maintain SCs in a quiescent state, and aberrant SST signaling contributes to SC overpopulation in colorectal cancer (CRC).

methodsThe proportion of SCs to NECs cells was quantified, by flow cytometry, in CRC cell lines and primary normal/tumor tissues based on cellular ALDH and SSTR1 levels, respectively. Doubling time and sphere-formation was used to evaluate cell proliferation and stemness. CRC cell lines were treated with exogenous SST and SST inhibitor cyclosomatostatin (cycloSST) and analyzed for changes in SCs and growth rate. Paracrine signaling between NECs and SCs was ascertained using transwell cultures of ALDH+ and SSTR1+ cells.

resultsIn CRC cell lines, the proportion of ALDH+ cells inversely correlates with proportion of SSTR1+ cells and with rate of proliferation and sphere-formation. While primary normal tissue shows SST and SSTR1 expression, CRC shows only SSTR1 expression. Moreover, ALDH+ cells did not show SST or SSTR1 expression. Exogenous SST suppressed proliferation but not ALDH+ population size or viability. Inhibition of SSTR1 signaling, via cycloSST treatment, decreased cell proliferation, ALDH+ cell population size and sphere-formation. When co-cultured with SSTR1+ cells, sphere-formation and cell proliferation of ALDH+ cells was inhibited.

conclusionThat each CRC cell line has a unique ALDH+/SSTR1+ ratio which correlates with its growth dynamics, suggests feedback mechanisms exist between SCs and NECs that contribute to regulation of SCs. The growth suppression by both SST and cycloSST treatments suggests that SST signaling modulates this feedback mechanism. The ability of SSTR1+ cells to decrease sphere formation and proliferation of ALDH+ cells in transwell cultures indicates that the ALDH subpopulation is regulated by SSTR1 via a paracrine mechanism. Since ALDH+ cells lack SST and SSTR1 expression, we conjecture that SST signaling controls the rate of NEC maturation as SCs mature along the NEC lineage, which contributes to quiescence of SCs and inhibition of proliferation.

Indexed as

Resting Phase, Cell CycleAldehyde DehydrogenaseCell Line, TumorCell ProliferationColonColonic NeoplasmsGene Expression Regulation, NeoplasticHumansIntestinal MucosaNeoplastic Stem CellsReceptors, SomatostatinSignal TransductionSomatostatinAldehyde DehydrogenaseReceptors, SomatostatinSomatostatinsomatostatin receptor type 1

Identifiers

PMID27927191
PMCPMC5142402
OpenAlexW2560227928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.